Skip to Main content Skip to Navigation
Journal articles

[Contribution of molecular biology to new diagnostic and/or prognostic markers characterization in cancerogenesis]

Florence de Fraipont 1
1 INSERM U823, équipe 5 (cibles diagnostiques ou thérapeutiques et vectorisation de drogues dans le cancer du poumon)
INSERM U823 - Institut d'oncologie/développement Albert Bonniot de Grenoble, UF cancérologie biologique et biothérapie
Abstract : During malignant transformation, cells accumulate genetic and epigenetic alterations. Since ten years, the knowledge of the whole human genome, associated with the development of new molecular biology techniques allowing global analysis, encouraged the identification of these anomalies. Thus, transcriptome studies with DNA chips allowed the characterization of genes groups whose expressions vary according to the type of tumors or according to their recurrence. We analysed adrenal tumors with DNA chips and tried to characterize recurring carcinomas. On the other hand, tumor suppressor genes expression could be inhibited by epigenetic modifications like gene promoter hypermethylation. With development of sensitive methods like PCR, methylation profile could be defined. We were interested in lung and head and neck tumors and tried to evaluate if the presence of methylated gene in bronchial lavage or in saliva could be a good marker for the early detection of a primary tumor or of a recurrence.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00312813
Contributor : Amandine Hurbin <>
Submitted on : Tuesday, August 26, 2008 - 3:47:02 PM
Last modification on : Wednesday, January 10, 2018 - 10:12:03 AM

Identifiers

  • HAL Id : inserm-00312813, version 1
  • PUBMED : 17264035

Collections

U823 | UGA

Citation

Florence de Fraipont. [Contribution of molecular biology to new diagnostic and/or prognostic markers characterization in cancerogenesis]. Annales de Biologie Clinique, John Libbey Eurotext, 2007, 65 (1), pp.21-6. ⟨inserm-00312813⟩

Share

Metrics

Record views

106